Evidence map›Paper›PMID 42479257›Full record

SynthesisInternational journal of clinical oncology2026

Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT

Takeshi Aoyama, Hirotoshi Iihara, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Chiyo K Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim and 16 more

Abstract readSystematic ReviewComparative Study
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Takeshi AoyamaDepartment of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. takeshi.aoyama@jfcr.or.jp.ORCID http://orcid.org/0000-0002-0767-2606
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Gifu, Japan.ORCID http://orcid.org/0000-0002-4171-454X
Masakazu AbeDepartment of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Shizuoka, Japan.
Makoto WadaDepartment of Psycho-Oncology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Osaka, Japan.
Keiko IinoSchool of Nursing, National College of Nursing, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho- cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Chiyo K ImamuraAdvanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Ayako OkuyamaGraduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan.
Keiko OzawaDivision of Survivorship, Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yong-Il KimDivision of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-ku, Osaka, 533-0024, Osaka, Japan.
Hidenori SasakiDivision of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Fukuoka, Japan.
Eriko SatomiDepartment of Palliative Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8521, Nara, Japan.
Ryuhei TanakaDepartment of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, 350-1298, Saitama, Japan.
Takako Eguchi NakajimaDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University, 2-16-1 Sugao, Miyamae, Kawasaki, 216-8511, Kanagawa, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Osaka, Japan.
Mayumi NodaNon-profit Organization Sasaeau-kai "Alpha", 518-7 Kawado-cho, Chuo-ku, Chiba, 260-0802, Chiba, Japan.
Kazumi HayashiDepartment of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shinnbashi, Minato-ku, Tokyo, 105-8461, Japan.
Takahiro HigashiDepartment of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, Institute of Medical Science, IMSUT Hospital, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Koji MatsumotoDivision of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, 673-0021, Hyogo, Japan.
Yoko MatsumotoNon-profit Organization Ehime Cancer Support "Orange-no-kai", 3-8- 24 Furukawaminami, Matsuyama, 790-0943, Ehime, Japan.
Kenji OkitaDepartment of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, 047-0032, Hokkaido, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Wakayama, Japan.
Kenjiro AogiDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, 791-0280, Ehime, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy-induced nausea and vomiting (CINV) significantly impact quality of life of patients with cancer. Although antiemetic guidelines exist for low-emetic chemotherapy (LEC), recommendations vary across international guidelines and direct evidence comparing 5-HT3 receptor antagonists (5-HT3 RAs) with dexamethasone monotherapy is lacking.

methodsWe conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for randomized controlled trials, nonrandomized comparative studies, and observational studies directly comparing 5-HT

resultsA systematic search identified 427 articles (87 from PubMed, 337 from the Cochrane Library, and three from Ichushi-Web), with three additional records identified through other sources. After the first screening of 430 articles, 425 records were excluded, and five records were used for full-text assessment. Following the second screening, five full-text articles were excluded for not meeting the inclusion criteria.

conclusionsThis systematic review identified no direct comparative evidence. Future efforts to strengthen the evidence base should include not only prospective comparative trials where feasible but also observational studies, real-world data analyses, and other complementary approaches that better reflect routine clinical practice.

Indexed as

AntiemeticsAntineoplastic AgentsDexamethasoneNauseaNeoplasmsSerotonin 5-HT3 Receptor AntagonistsVomitingHumansQuality of LifeAntiemeticsAntineoplastic AgentsDexamethasoneSerotonin 5-HT3 Receptor Antagonists5-HT3Chemotherapy-induced nausea and vomitingDexamethasoneLow emetogenic chemotherapyreceptor antagonistsSystematic review

Identifiers

PMID42479257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.